Bale M J, Jones R N, Erwin M E, Koontz F P, Gerlach E H, Murray P R, Washington J A
Special Microbiology, University of Iowa, College of Medicine, Iowa City 52242.
J Clin Microbiol. 1992 Jan;30(1):225-6. doi: 10.1128/jcm.30.1.225-226.1992.
A multilaboratory study was performed to establish broth microdilution MIC quality control (QC) guidelines for 10 investigational drugs which previously demonstrated significant activity against Haemophilus influenzae. MIC QC ranges for H. influenzae ATCC 49247 with Haemophilus test medium were determined by using multiple contemporary lots of Haemophilus test medium and the National Committee for Clinical Laboratory Standards' recommended numbers of replicate tests. On the basis of these results, QC ranges (generally modal MIC +/- one log2 dilution) are proposed for cefdinir, cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. The proposed QC guidelines for clarithromycin and temafloxacin were recently accepted by the National Committee for Clinical Laboratory Standards.
进行了一项多实验室研究，以建立10种研究性药物的肉汤微量稀释最低抑菌浓度（MIC）质量控制（QC）指南，这些药物先前已证明对流感嗜血杆菌具有显著活性。使用多个当代批次的嗜血杆菌测试培养基和美国国家临床实验室标准委员会推荐的重复测试次数，确定了流感嗜血杆菌ATCC 49247在嗜血杆菌测试培养基中的MIC QC范围。基于这些结果，提出了头孢地尼、头孢吡肟、头孢他美、头孢匹罗、头孢布烯、氟罗沙星、替马沙星、克拉霉素、RP59500和曲氟沙星的QC范围（一般为模态MIC +/- 一个log2稀释度）。克拉霉素和替马沙星的拟议QC指南最近已被美国国家临床实验室标准委员会接受。
